These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10384152)

  • 41. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In situ demonstration of renal-cell-carcinoma-specific T-cell clones.
    Caignard A; Guillard M; Gaudin C; Escudier B; Triebel F; Dietrich PY
    Int J Cancer; 1996 May; 66(4):564-70. PubMed ID: 8635875
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systematic analysis of the combinatorial nature of epitopes recognized by TCR leads to identification of mimicry epitopes for glutamic acid decarboxylase 65-specific TCRs.
    Uemura Y; Senju S; Maenaka K; Iwai LK; Fujii S; Tabata H; Tsukamoto H; Hirata S; Chen YZ; Nishimura Y
    J Immunol; 2003 Jan; 170(2):947-60. PubMed ID: 12517961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
    Zhou J; Dudley ME; Rosenberg SA; Robbins PF
    J Immunother; 2005; 28(1):53-62. PubMed ID: 15614045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ribosomal scanning past the primary initiation codon as a mechanism for expression of CTL epitopes encoded in alternative reading frames.
    Bullock TN; Eisenlohr LC
    J Exp Med; 1996 Oct; 184(4):1319-29. PubMed ID: 8879204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.
    Slager EH; van der Minne CE; Krüse M; Krueger DD; Griffioen M; Osanto S
    J Immunol; 2004 Apr; 172(8):5095-102. PubMed ID: 15067093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.
    Guilloux Y; Lucas S; Brichard VG; Van Pel A; Viret C; De Plaen E; Brasseur F; Lethé B; Jotereau F; Boon T
    J Exp Med; 1996 Mar; 183(3):1173-83. PubMed ID: 8642259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.
    Gaugler B; Brouwenstijn N; Vantomme V; Szikora JP; Van der Spek CW; Patard JJ; Boon T; Schrier P; Van den Eynde BJ
    Immunogenetics; 1996; 44(5):323-30. PubMed ID: 8781117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. +1 Frameshifting as a novel mechanism to generate a cryptic cytotoxic T lymphocyte epitope derived from human interleukin 10.
    Saulquin X; Scotet E; Trautmann L; Peyrat MA; Halary F; Bonneville M; Houssaint E
    J Exp Med; 2002 Feb; 195(3):353-8. PubMed ID: 11828010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
    Mandruzzato S; Rossi E; Bernardi F; Tosello V; Macino B; Basso G; Chiarion-Sileni V; Rossi CR; Montesco C; Zanovello P
    J Immunol; 2002 Oct; 169(7):4017-24. PubMed ID: 12244204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel melanoma gene (MG50) encoding the interleukin 1 receptor antagonist and six epitopes recognized by human cytolytic T lymphocytes.
    Mitchell MS; Kan-Mitchell J; Minev B; Edman C; Deans RJ
    Cancer Res; 2000 Nov; 60(22):6448-56. PubMed ID: 11103812
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy.
    Rosenberg SA; Tong-On P; Li Y; Riley JP; El-Gamil M; Parkhurst MR; Robbins PF
    J Immunol; 2002 Mar; 168(5):2402-7. PubMed ID: 11859131
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
    Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
    Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation.
    Toso JF; Oei C; Oshidari F; Tartaglia J; Paoletti E; Lyerly HK; Talib S; Weinhold KJ
    Cancer Res; 1996 Jan; 56(1):16-20. PubMed ID: 8548758
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.
    Godet Y; Moreau-Aubry A; Guilloux Y; Vignard V; Khammari A; Dreno B; Jotereau F; Labarriere N
    J Exp Med; 2008 Oct; 205(11):2673-82. PubMed ID: 18936238
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.
    Ayyoub M; Stevanovic S; Sahin U; Guillaume P; Servis C; Rimoldi D; Valmori D; Romero P; Cerottini JC; Rammensee HG; Pfreundschuh M; Speiser D; Lévy F
    J Immunol; 2002 Feb; 168(4):1717-22. PubMed ID: 11823502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
    Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB
    J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma.
    Nishizaka S; Gomi S; Harada K; Oizumi K; Itoh K; Shichijo S
    Cancer Res; 2000 Sep; 60(17):4830-7. PubMed ID: 10987294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.